title: [The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma].
abstract: OBJECTIVE
  In order to investigate the interaction between the cytokines and keratinocyte and determine the role of cytokines in hyperproliferative of chronic otitis media with cholesteatoma, we observe the expression of matrix metalloproteinase 9 (MMP9), vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF) and its receptor (KGFR) in middle ear cholesteatoma.
  
  
  METHODS
  We examined the expression of MMP9, VEGF, KGF, KGFR and Ki-67 by immunohistochemistry in 50 specimens from chronic otitis media with cholesteatoma and 15 specimens from the normal skin of external auditory meatus. Ki-67 as an evaluation of cholesteatoma proliferation markers were used to detect the keratinocyte proliferative activity.
  
  
  RESULTS
  (1) The expression of VEGF and MMP9 in cholesteatoma specimens was higher than normal skin, and the difference was statistically significant (t = 4.914, P < 0.01; t = 3.284, P < 0.01). (2) The expression of KGF and KGFR in middle ear tissues was higher than normal skin, and the difference was statistically significant (t = 4.814, P < 0.01; t = 3.104, P < 0.01); The expression of KGF and KGFR increased, and the expression of Ki-67 also correspondly increased in the cholesteatoma. (3) In the tissue MMP9 and VEGF were positive. Mean optical density increased as well. KGF expression also increased accordingly.
  
  
  CONCLUSIONS
  MMP9, VEGF, KGF and KGFR proteins played an important role in hyperproliferation of cholesteatoma tissues. VEGF, MMP9 and KGF had a synergistic effect in hyperproliferation of cholesteatoma tissues.
authors.forename: Zhongshou
authors.initials: Z
authors.lastname: Zhu
authors.forename: Yiyun
authors.initials: Y
authors.lastname: Hong
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Guanwen
authors.initials: G
authors.lastname: He
authors.forename: Shengnan
authors.initials: S
authors.lastname: Ye
mesh_terms: D018424:Cholesteatoma, Middle Ear / Q000473:pathology*; D016207:Cytokines / Q000378:metabolism*; D004424:Ear Canal / Q000378:metabolism; D004432:Ear, Middle / Q000378:metabolism; D051523:Fibroblast Growth Factor 7 / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D015603:Keratinocytes / Q000166:cytology*; D019394:Ki-67 Antigen / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D010033:Otitis Media / Q000473:pathology; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D016207:Cytokines; C496453:FGF7 protein, human; D019394:Ki-67 Antigen; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D051523:Fibroblast Growth Factor 7; C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9